{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:40:39Z","timestamp":1687740039283},"reference-count":23,"publisher":"Japanese Leprosy Association","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn.J.Leprosy","Nihon Hansenbyo Gakkai Zasshi","Jpn J Lepr"],"published-print":{"date-parts":[[2011]]},"DOI":"10.5025\/hansen.80.275","type":"journal-article","created":{"date-parts":[[2012,9,28]],"date-time":"2012-09-28T18:56:17Z","timestamp":1348858577000},"page":"275-285","source":"Crossref","is-referenced-by-count":4,"title":["Japanese guideline on thalidomide usage in the management of erythema nodosum leprosum"],"prefix":"10.5025","volume":"80","author":[{"given":"Norihisa","family":"ISHII","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"ISHIDA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"OKANO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoaki","family":"OZAKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaich","family":"GIDOH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimiko","family":"KUMANO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamichi","family":"GOTO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiko","family":"NOGAMI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"HATANO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akatsuki","family":"YAMADA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie Roselyne","family":"YOTSU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2941","reference":[{"key":"1"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.5025\/hansen.71.3"},{"key":"3"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Sheskin J: Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 6: 303-306, 1965.","DOI":"10.1002\/cpt196563303"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B: Antitumor activity of thalidomide in refractorymultiple myeloma. N Engl J Med 341:1565-1571, 1999.","DOI":"10.1056\/NEJM199911183412102"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Pearson JM, Vedagiri M : Treatment of moderately severe erythema nodosum leprosum with thalidomide- a double-blind controlled trial. Lepr Rev 40, 111-116, 1969.","DOI":"10.5935\/0305-7518.19690022"},{"key":"7","unstructured":"7) Sheskin J, Convit J: Results of a double blind study of the influence of thalidomide on the lepra reaction. Int J Lepr 37, 135-146, 1969."},{"key":"8","unstructured":"8) Iyer CG, Languillon J, Ramanujam K, Tarabini-Castellani G, De las Aguas JT, Bechelli LM, Uemura K, Martinez Dominguez V, Sundaresan T: WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ 45: 719-732, 1971."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Waters MF: An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum. Lepr Rev 42, 26-42, 1971.","DOI":"10.5935\/0305-7518.19710004"},{"key":"10","unstructured":"10) Iyer CG, Ramu G: An open trial with clofazimine in the management of recurrent lepra reaction using thalidomide as a control drug. Lepr India 48, 690-694, 1976."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Villahermosa LG, Fajardo TT Jr, Abalos RM, Balagon MV, Tan EV, Cellona RV, Palmer JP, Wittes J, Thomas SD, Kook KA, Walsh GP, Walsh DS: A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum. Am J Trop Med Hyg 72: 518-526, 2005.","DOI":"10.4269\/ajtmh.2005.72.518"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-879X2006005000070"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2009.00534.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Van Veen NH, Lockwood DN, Van Brakel WH, Ramirez J Jr, Richardus JH: Intervention for erythema nodosum leprosum. A Cochrane review. Lepr Rev 80: 355-372, 2009.","DOI":"10.1002\/14651858.CD006949.pub2"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)88289-2"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(92)90088-6"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, Sarno EN: The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 168: 408-414, 1993.","DOI":"10.1093\/infdis\/168.2.408"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.5025\/hansen.75.191"},{"key":"19"},{"key":"20"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2007.03203.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"25) Uyemura K, Dixon JF, Wong L, Rea TH, Modlin RL: Effect of cyclosporine A in erythema nodosum leprosum. J Immunol 137: 3620-3623, 1986.","DOI":"10.4049\/jimmunol.137.11.3620"},{"key":"23","doi-asserted-by":"crossref","unstructured":"28) Singhal S, Mehta J: Thalidomide in cancer. Biomed Pharmacother 56: 4-12, 2002.","DOI":"10.1016\/S0753-3322(01)00146-9"}],"container-title":["JAPANESE JOURNAL OF LEPROSY"],"original-title":["\u3089\u3044\u6027\u7d50\u7bc0\u6027\u7d05\u6591\uff08ENL\uff09\u306b\u5bfe\u3059\u308b\u30b5\u30ea\u30c9\u30de\u30a4\u30c9\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3"],"language":"en","deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:06:05Z","timestamp":1687737965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/hansen\/80\/3\/80_275\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.5025\/hansen.80.275","relation":{},"ISSN":["1342-3681","1884-314X"],"issn-type":[{"value":"1342-3681","type":"print"},{"value":"1884-314X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}